Merck & Co.’s Strategic Positioning and Market Potential Justify Buy Rating Despite Challenges

Analyst Asad Haider of Goldman Sachs maintained a Buy rating on Merck & Company, retaining the price target of $94.00.

Asad Haider has given his Buy rating due to a combination of factors related to Merck & Company’s strategic positioning and market potential. Despite challenges in the Chinese market, particularly with the Gardasil vaccine, Haider sees potential for recovery and growth. The company’s efforts to manage inventory and stimulate demand through promotional activities, such as offering free doses, are viewed positively.
Additionally, while the Chinese market presents certain obstacles, it constitutes a small portion of Merck’s overall revenue. Haider emphasizes the importance of the U.S. market, where Gardasil trends are being closely monitored. The potential for changes in dosing regimens could impact revenue, but the overall outlook remains optimistic. Haider believes that Merck’s proactive strategies and market opportunities justify the Buy rating, anticipating long-term growth and resilience in the face of current challenges.

In another report released on August 14, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $96.00 price target.

MRK’s price has also changed slightly for the past six months – from $85.600 to $84.930, which is a -0.78% drop .